PMID- 38352733
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240215
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 10
IP  - 3
DP  - 2024 Feb 15
TI  - Bioinformatic analysis reveals prognostic value and immunotherapy potential of 
      Siglec-15 in laryngeal squamous cell carcinoma.
PG  - e25266
LID - 10.1016/j.heliyon.2024.e25266 [doi]
LID - e25266
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is the ultimate common 
      malignant head and neck cancer with dismal prognosis. The expression pattern and 
      clinical significance of Siglec-15 (Sialic acid-binding immunoglobulin-like 
      lectin 15) in LSCC are poorly understood. In order to lay the groundwork for 
      future immune-related research on Siglec-15 in LSCC, we set out to study its 
      expression and prognostic importance in the disease, as well as to use 
      bioinformatics to investigate the immune features modulated by Siglec-15 in LSCC. 
      METHODS: 1 in circle In order to get the gene expression profile and clinical data for TCGA 
      head and neck cancer (TCGA-HNSC), you may access the relevant data from UCSC xena 
      and use 110 cases of laryngeal cancer as a training set. Two datasets, GSE27020 
      and GSE25727, were obtained from the GEO databank and utilized as validation 
      sets. These datasets include expression profiles and clinical information. The 
      Siglec-15 gene and immune characteristics were analyzed by bioinformatics 
      methods. 2 in circle Retrospectively collected routine paraffin specimens from patients 
      with pathological diagnosis of squamous cell carcinoma from December 2012 to 
      November 2015 in Sun Yat-sen Memorial Hospital and fresh frozen tissue of 
      patients from June 2021 to March 2022. Immunohistochemistry method, 
      immunofluorescence technique and real-time quantitative PCR was used to examine 
      the difference of Siglec-15 appearance in LSCC tissue and adjacent tissue, and 
      its correlation of prognosis, clinic pathological characteristics and CD8+T 
      lymphocyte infiltration. Using human laryngeal cancer cell line (LCC), we studied 
      the influence of Siglec-15 in cell proliferation and invasion. RESULTS: We 
      identified Siglec-15 was upregulated in LSCC. The patients in Siglec-15 high 
      expression group had a poor overall survival (OS) based on the clinical 
      information from TGCA and 111 LSCC patients that hospitalized in Sun Yat-sen 
      Memorial Hospital. The COX regression analysis indicated Siglec-15 as an 
      independent predictor for poor prognosis of LSCC. Bioinformatic analysis 
      suggested that the high expression of Siglec-15 shape an immune suppressive tumor 
      microenvironment (TEM), leading to poor response to immunotherapy in LSCC. 
      Siglec-15 enhanced cell invasion and proliferation, as we showed in vitro. 
      CONCLUSION: Our study support Siglec-15 as a potential predictor for LSCC 
      prognosis and an attractive target for LSCC immunotherapy.
CI  - (c) 2024 The Authors.
FAU - Chen, Xiaoting
AU  - Chen X
AD  - Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
AD  - Heyou Hospital, No. 1 of Heren Road, Junlan Community, Beijiao Town, Shunde 
      District, Foshan City, Guangdong Province, China.
FAU - Cai, Qian
AU  - Cai Q
AD  - Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Wong, Kaiyi
AU  - Wong K
AD  - Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Shen, Ximing
AU  - Shen X
AD  - Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Guan, Zhong
AU  - Guan Z
AD  - Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20240130
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10861961
OTO - NOTNLM
OT  - Bioinformatic analysis
OT  - Immune infiltration
OT  - Immunotherapy
OT  - Laryngeal squamous cell carcinoma
OT  - Siglec-15
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/02/14 06:43
MHDA- 2024/02/14 06:44
PMCR- 2024/01/30
CRDT- 2024/02/14 03:57
PHST- 2023/09/20 00:00 [received]
PHST- 2024/01/23 00:00 [revised]
PHST- 2024/01/23 00:00 [accepted]
PHST- 2024/02/14 06:44 [medline]
PHST- 2024/02/14 06:43 [pubmed]
PHST- 2024/02/14 03:57 [entrez]
PHST- 2024/01/30 00:00 [pmc-release]
AID - S2405-8440(24)01297-0 [pii]
AID - e25266 [pii]
AID - 10.1016/j.heliyon.2024.e25266 [doi]
PST - epublish
SO  - Heliyon. 2024 Jan 30;10(3):e25266. doi: 10.1016/j.heliyon.2024.e25266. 
      eCollection 2024 Feb 15.